NewAmsterdam Pharma Company N.V. (NAMS)
- Previous Close
21.44 - Open
21.13 - Bid 21.92 x 100
- Ask 22.01 x 100
- Day's Range
21.13 - 22.09 - 52 Week Range
5.63 - 26.35 - Volume
62,241 - Avg. Volume
230,098 - Market Cap (intraday)
1.963B - Beta (5Y Monthly) 0.02
- PE Ratio (TTM)
-- - EPS (TTM)
-2.15 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
33.29
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
www.newamsterdampharma.comRecent News: NAMS
Performance Overview: NAMS
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NAMS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NAMS
Valuation Measures
Market Cap
1.96B
Enterprise Value
1.62B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
128.23
Price/Book (mrq)
6.81
Enterprise Value/Revenue
115.16
Enterprise Value/EBITDA
-9.17
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-27.70%
Return on Equity (ttm)
-49.26%
Revenue (ttm)
14.09M
Net Income Avi to Common (ttm)
-176.94M
Diluted EPS (ttm)
-2.15
Balance Sheet and Cash Flow
Total Cash (mrq)
340.45M
Total Debt/Equity (mrq)
0.02%
Levered Free Cash Flow (ttm)
-72M